212 related articles for article (PubMed ID: 38599892)
1. Updates in induction immunosuppression regimens for intestinal transplantation.
Paulo Guzman J; Maklad M; Osman M; Elsherif A; Fujiki M
Hum Immunol; 2024 May; 85(3):110800. PubMed ID: 38599892
[TBL] [Abstract][Full Text] [Related]
2. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
4. Update on immunosuppressive strategies in intestinal transplantation.
Merola J; Shamim A; Weiner J
Curr Opin Organ Transplant; 2022 Apr; 27(2):119-125. PubMed ID: 35232925
[TBL] [Abstract][Full Text] [Related]
5. Association of More Intensive Induction With Less Acute Rejection Following Intestinal Transplantation: Results of 445 Consecutive Cases From a Single Center.
Vianna R; Farag A; Gaynor JJ; Selvaggi G; Tekin A; Garcia J; Beduschi T
Transplantation; 2020 Oct; 104(10):2166-2178. PubMed ID: 31929425
[TBL] [Abstract][Full Text] [Related]
6. Intestinal and multivisceral transplantation immunosuppression protocols--literature review.
Trevizol AP; David AI; Dias ER; Mantovani D; Pécora R; D'Albuquerque LA
Transplant Proc; 2012 Oct; 44(8):2445-8. PubMed ID: 23026616
[TBL] [Abstract][Full Text] [Related]
7. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.
Cheng EY; Everly MJ; Kaneku H; Banuelos N; Wozniak LJ; Venick RS; Marcus EA; McDiarmid SV; Busuttil RW; Terasaki PI; Farmer DG
Transplantation; 2017 Apr; 101(4):873-882. PubMed ID: 27490417
[TBL] [Abstract][Full Text] [Related]
9. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
Cheng EY; Kaneku H; Farmer DG
Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
[TBL] [Abstract][Full Text] [Related]
10. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
11. Novel Immunosuppression in Solid Organ Transplantation.
Konda P; Golamari R; Eisen HJ
Handb Exp Pharmacol; 2022; 272():267-285. PubMed ID: 35318509
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective.
Stratta RJ; Farney AC; Rogers J; Orlando G
Expert Rev Clin Immunol; 2014 Jan; 10(1):117-32. PubMed ID: 24236648
[TBL] [Abstract][Full Text] [Related]
13. Antibody induction versus corticosteroid induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressant strategies for intestinal transplantation: a review of a tolerogenic regimen.
Flynn B; Park BK; Bond G; McGhee W; Mazariegos G; Sindhi R; Reyes J; Abu-Elmagd K
Prog Transplant; 2005 Mar; 15(1):60-4. PubMed ID: 15839373
[TBL] [Abstract][Full Text] [Related]
15. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
16. Intestinal transplantation: evolution in immunosuppression protocols.
Pirenne J; Kawai M
Curr Opin Organ Transplant; 2009 Jun; 14(3):250-5. PubMed ID: 19373085
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transplantation in children: a review of immunotherapy regimens.
Nayyar NS; McGhee W; Martin D; Sindhi R; Soltys K; Bond G; Mazariegos GV
Paediatr Drugs; 2011 Jun; 13(3):149-59. PubMed ID: 21500869
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression Protocols in Intestinal and Multivisceral Transplantation-A Literature Review.
Ferreira MA; Ouverney LFF; Figueiredo MC; David AI
Transplant Proc; 2023; 55(6):1431-1436. PubMed ID: 37088617
[TBL] [Abstract][Full Text] [Related]
19. Induction Versus Maintenance Immunosuppression After Intestinal Transplant: Determining Which Treatment Most Impacts Long-Term Patient And Graft Survival.
Gentilini MV; Perez-Illidge L; Pedraza N; Nemirovsky SI; Fernandez MF; Ramisch D; Solar H; Rumbo M; Rumbo C; Gondolesi GE
Exp Clin Transplant; 2022 Dec; 20(12):1105-1113. PubMed ID: 36718010
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
